BioAsia 2013, attracts regulators from across the globe

Jan. 18, 2013 - PRLog -- Hyderabad, 18th January 2013: In a significant development ‘BioAsia’ 2013, for the first time, will witness the participation of top officials from biopharma, biotech and health regulatory agencies from across the globe. Prominent amongst the confirmations are USA, South Africa, Sri lanka, Philippines, Czech Republic, Malaysia, Jordan, republic of Lithuania, Ghana, London, Sweden and India. ‘BioAsia’ 2013, the 10th edition of the much anticipated global platform for Biotechnology and Life sciences will be held at the Hyderabad International Convention Centre (HICC), Hyderabad from 28th to 30th January 2013.

Commenting on the development, Mr. Shakthi Nagappan, CEO, ‘BioAsia’ said, “BioAsia’s growing prominence as an influential and industry shaping platform for biotechnology and biopharma has drawn the attention of the regulatory community. Participation of these regulators – a very significant section, who shape the industry, is a boost for the platform and will greatly benefit the participating companies”.

Key Attendees

Assistant Country Director (Clinical Research)- U.S. FDA India Office Medical

Medical Assessor in Biological Unit of Licensing Division at MHRA (London, UK)

Minister of Health - The Republic of South Africa  

Head of Biotechnology Section, National Pharmaceutical Control Bureau, Pharmaceutical Services Division, Ministry of Health- Malaysia

Deputy Director of Regulatory Affairs at State Institute for Drug Control- Czech Republic  

Head of Registration Department, Jordan Food & Drug Administration- Jordan

Director, State Health Care Accreditation Agency, Ministry of Health- Republic of Lithuania

Director, STI, Ministry of Environment, Science & Technology- Ghana

Director, International Collaboration & Networks, Swedish Government Agency for Innovation Systems (VINNOVA)- Sweden

Director (Medical Technology & Supplies), Ministry of Health, Sri Lanka

Assistant Secretary of Health, USEC Department of Health, Philippines

Top officials from from DCGI, ICMR, DBT, DST, DoP, etc.  

The participating regulators will provide a broader perspective of understanding on the existing regulations pursued in their respective markets and across the globe leading to an in-depth understanding on the existing regulatory frameworks and requirements. This knowledge thereby will benefit the Indian companies interested in expanding their business operations and establishing footprints in these regions through exports, joint ventures, marketing, R&D, etc.

“We are extremely glad that the Ministry of Commerce and Industry through the Pharmaceutical Export Promotion Council of India, recognizing the importance of this effort, has come forward and agreed to support this initiative of ‘BioAsia’” he added.

Commenting further Mr. Deepak Sood, Business Director, Lonza India said, “‘BioAsia’ as a platform has been on an evolution of steady growth each year adding new dimensions to spur the expansion of the industry and directly benefiting the entire ecosystem. The participation of the regulators gives further momentum to the growth of the industry”.

The regulatory meet, in addition to helping the companies understand the regulations, will also offer a platform for the regulators to converge and deliberate on various aspects of harmonizing the regulations globally. The organizers are confident that the regulators meet, will reemphasize the commitment of ‘BioAsia’ towards achieving positive changes in the biotechnology and biopharmaceutical industry.

Commenting on the event, Dr. PV Appaji, Director General, Pharmexcil said “PHARMEXCIL and the Ministry of Commerce are working extremely hard towards achieving the exports targets of USD 25Bn by 2014-15 from the current level of USD 13.5 Bn.  We strongly believe that the presence of top regulators from important export destinations and some new markets during ‘BioAsia’ 2013 will be a great step forward in achieving this goal. The response so far from the Indian Industries towards this activity has been overwhelming and we are expecting more than 200 Indian companies to participate and interact with the regulators”

About BioAsia: ‘BioAsia’ is born with a vision to enhance, enrich and encourage newer innovations, path-breaking discoveries and effective solutions in the biotechnology industry by offering a vibrant global platform for convergence of the key stakeholders - Biotech & Biopharma Companies, research institutions, academia,  investors, service providers, policy makers, regulators and analysts. ‘BioAsia’ is focused in its efforts - to drive the growth of the industry by enabling an effective environment for fostering collaborations, JV’s M&A’s; ensure knowledge and experience sharing by global industry players to benefit all stakeholders; promote innovations and initiatives through appropriate awards and recognitions; play a pivotal role in advocating issues to the policy makers and chartering the road-map of bio-technology. ‘BioAsia’ is a dynamic platform for companies -to exhibit, launch and showcase their unique strengths, products and services. ‘BioAsia’ is playing the role of a key catalyst in mobilizing all elements that are required to drive the growth of the emerging industry of Biotechnology as well as optimize the immense business potential of biotech. On a larger level, ‘BioAsia’ is working to drive a global transformation from the treatment of illness to wellness.

About FABA (Federation of Asian Biotech Associations): The Federation of Asian Biotech Associations [FABA], is a non-profit registered society engaged in various activities related to promoting Biotechnology in Asian countries. FABA, headquartered at Hyderabad made its humble beginning in 2004 and has achieved a significant landmark in creating a common platform for interaction among member countries and discuss the issues of common interest for improving the biotech space including Technology Transfer, resource sharing, business collaborations, Industry-Academia linkage, cross border trade and investments, etc. among its member countries., FABA has a strong network base in 20 Asian countries including China, India, Bangladesh, Malaysia, Philippines, Russia, Kazakhstan, Pakistan, Israel, Iran, Indonesia, Nepal, Japan, South Korea, Singapore, Thailand, Sri Lanka and UAE. Besides, FABA has entered into working understandings with Non-Asian organizations like European Federation of Biotechnology, Biocat (Spain), Maryland India Business Round Table (USA), Bio Industry Park (Italy) and Association of German Biotech companies (Germany), etc.

Pharmexcil: Pharmaceutical Export Promotion Council (Pharmexcil) was set up by the Ministry of Commerce and Industry, Government of India in 2004 is located at Hyderabad for promotion of pharmaceutical exports from India. Various pharmaceutical products, namely, bulk drugs and its intermediates, formulations, biotech and biological products, herbal products, ayurvedic, unani and homeopathic medicines, diagnostics, surgical, nutraceuticals, collaborative research, contract manufacturing, clinical trials and consultancy, etc. are covered under its purview. Pharmexcil takes up several external trade promotion activities by organizing trade delegations outside India, arranging buyer-seller meetings, international seminars, interactive meetings on exports related issues, make suggestions to Govt. of India on policy issues relating to pharma exports, make representations to Govt. of India and other agencies in India and abroad to get amicable solutions for the common problems of the industry, etc.

For further information queries please contact

Meeta Singh/Ben Paul Thomas, Perfect Relations @ 9949065300/8790432354